WINNIPEG, MANITOBA -- (Marketwire) -- 02/04/13 -- Miraculins Inc. (TSX VENTURE: MOM), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs, is pleased to announce that it will receive the Life Science Company of the Year Award from the Life Science Association of Manitoba at an awards ceremony on February 13, 2013. The award is presented annually to a private sector company based in Manitoba that has made a positive impact on the life sciences sector in the past year and is active in paving the road toward future wealth and job creation in the province. Past Life Science Company of the Year Award winners include IMRIS, Biovail and Cangene.
The Life Science Association of Manitoba (LSAM) presents its annual Life Science Awards as a way to recognize the leaders and innovators of the life science community. With its selection as Life Science Company of the Year, Miraculins has been recognized for distinguishing itself from its peers with strong overall company performance, demonstrating leadership and showing significant achievement.
"We are pleased to acknowledge Miraculins as the Life Science Company of the Year for 2012," said Tracey Maconachie, President of LSAM. "The life science industry in Manitoba, which now accounts for 7% of the province's GDP, is loaded with exceptional companies, with Miraculins serving as a prime example of the type of burgeoning life science success stories that Manitoba is offering the world."
"We are honoured to have been recognized by LSAM for our accomplishments to date, and for our potential as we move forward," said Christopher J. Moreau, President and Chief Executive Officer of Miraculins Inc. "We are proud to share news of this award with our shareholders, investors and customers, without whom we would not have been able to reach this point in our corporate development. Furthermore, we are pleased to be acknowledged amongst the many deserving life science companies in Manitoba, and are proud to be a part of this important sector, with a very supportive industry association and a provincial government with a true appreciation for innovation."
About Miraculins Inc.
Miraculins is a medical diagnostic company focused on acquiring, developing and commercializing non-invasive tests for unmet clinical needs. A significant number of promising diagnostic opportunities remain un-commercialized because of the sizable gap between the discovery stage, when research institutions are typically involved, and the commercialization stage, when the larger commercial enterprises become interested. Miraculins has direct experience in bridging this gap. The Company's PreVu® technology is a revolutionary new coronary artery disease risk assessment technology that measures cholesterol levels in a patient's skin non-invasively, painlessly and without the need for fasting. Miraculins is also advancing a suite of biomarkers to aid in the early detection of the devastating disease of pregnancy known as preeclampsia. The Company's preeclampsia program is partnered with Alere Inc., one of the world's largest diagnostic companies. For more information, visit www.miraculins.com.
Most Popular Stories
- Consumer Spending Will Offset Sequester: Economists
- Hispanic Grads Pass Their Peers in College Enrollment
- AT&T Seeks to Fill 120 Jobs in South Carolina
- Gas Prices Expected to Stay High
- California Considers Oil Tax to Fund Schools
- Dude! California Beach Parking Plan Making Waves
- Ford's Supplier Diversity Program Turns 35
- Yahoo to Pay $1.1 Billion for Tumblr
- NTSB Wants to Lower Blood Alcohol Limit to 0.05
- Boise Terror Suspect Pleads Not Guilty